SUMMARY OF THE RECOMMENDATION
The U.S. Preventive Services Task Force (USPSTF) strongly recommends that clinicians discuss aspirin chemoprevention with adults who are at increased risk for coronary heart disease (see Clinical Considerations). Discussions with patients should address both the potential benefits and harms of aspirin therapy. This is a grade A recommendation. (See Appendix Table 1 for a description of the USPSTF classification of recommendations.)
The USPSTF found good evidence that aspirin decreases the incidence of coronary heart disease in adults who are at increased risk for heart disease. It also found good evidence that aspirin increases the incidence of gastrointestinal bleeding and fair evidence that aspirin increases the incidence of hemorrhagic strokes. (See Appendix Table 2 for a description of the USPSTF classification of levels of evidence.) The USPSTF concluded that the balance of benefits and harms is most favorable in patients at high risk for coronary heart disease (those with a 5-year risk Ն 3%) but is also influenced by patient preferences.
CLINICAL CONSIDERATIONS
Decisions about aspirin therapy should take into account overall risk for coronary heart disease. Risk assessment should include asking about the presence and severity of the following risk factors: age, sex, diabetes, elevated total cholesterol levels, low levels of high-density lipoprotein cholesterol, elevated blood pressure, family history (in younger adults), and smoking. Tools that incorporate specific information on multiple risk factors provide more accurate estimation of cardiovascular risk than categorizations based simply on counting the numbers of risk factors (www.med-decisions.com) (1).
Men older than 40 years of age, postmenopausal women, and younger persons with risk factors for coronary heart disease (for example, hypertension, diabetes, or smoking) are at increased risk for heart disease and may wish to consider aspirin therapy. The Table shows how estimates of the type and magnitude of benefits and harms associated with aspirin therapy vary with an individual's underlying risk for coronary heart disease. Although balance of benefits and harms is most favorable in high-risk persons (those with a 5-year risk Ն 3%), some persons at lower risk may consider the potential benefits of aspirin to outweigh the potential harms.
Discussions about aspirin therapy should focus on potential coronary heart disease benefits, such as prevention of myocardial infarction, and potential harms, such as gastrointestinal and intracranial bleeding. Discussions should take into account individual preferences and risk aversions concerning myocardial infarction, stroke, and gastrointestinal bleeding. Although the optimal timing and frequency of discussions related to aspirin therapy are unknown, reasonable options include every 5 years in middle-aged and older persons or when other cardiovascular risk factors are detected.
Most participants in the primary prevention trials of aspirin therapy have been men between 40 and 75 years of age. Current estimates of benefits and harms may not Clinical Guidelines be as reliable for women and older men. Although older patients may derive greater benefits because they are at higher risk for coronary heart disease and stroke, their risk for bleeding may be higher. Uncontrolled hypertension may attenuate the benefits of aspirin in reducing coronary heart disease. 
SCIENTIFIC EVIDENCE Epidemiology and Clinical Background
Cardiovascular disease, including ischemic coronary heart disease, stroke, and peripheral vascular disease, is the leading cause of death in the United States (3). Yearly, over 1 million Americans experience new or recurrent myocardial infarction or fatal coronary heart disease. Most events occur in older persons and those with recognized risk factors for cardiovascular disease, including high cholesterol level, high blood pressure, diabetes, or a history of smoking. The early-documented and clear success of aspirin in preventing further clinical disease in some patients with known heart disease (secondary prevention) raised interest in aspirin as a potential primary preventive intervention in men and women without known heart disease (4). Two early randomized trials of aspirin had conflicting results, however, and lacked sufficient power to estimate major harms, such as gastrointestinal bleeding and hemorrhagic stroke (5, 6) . Thus, the role of aspirin in primary prevention has remained controversial. The new USPSTF recommendation incorporates additional data from three recent trials and provides more reliable estimates of both benefits and harms of aspirin in patients without known heart disease.
Efficacy of Chemoprevention
Five trials have examined the effects of daily or every-other-day aspirin for the primary prevention of cardiovascular events over periods of 4 to 7 years (7-9). Most participants were men older than 50 years of age. Meta-analysis of pooled data from all of the studies showed that aspirin therapy reduced the risk for coronary heart disease by 28% (summary odds ratio, 0.72 [95% CI, 0.60 to 0.87]). Summary estimates showed no significant effects of aspirin on total mortality (odds ratio, 0.93 [CI, 0.84 to 1.02]) and stroke (odds ratio, 1.02 [CI, 0.85 to 1.23]).
Harms of Chemoprevention
These five primary prevention trials, and a larger number of randomized, controlled trials of secondary prevention that enrolled patients with heart disease or stroke, demonstrate that aspirin increases rates of gastrointestinal bleeding. Estimated rates of major gastrointestinal bleeding episodes are approximately 2 to 4 per † Nonfatal acute myocardial infarction and fatal coronary heart disease. Five-year risks of 1%, 3%, and 5% are equivalent to 10-year risks of 2%, 6%, and 10%, respectively. ‡ Data from secondary prevention trials suggest that increases in hemorrhagic stroke may be offset by reduction in other types of stroke in patients at very high risk for cardiovascular disease (Ն10% 5-year risk). § Rates may be two to three times higher in persons older than 70 years of age.
Clinical Guidelines Aspirin for the Primary Prevention of Cardiovascular Events: Recommendation and Rationale 1000 middle-aged persons (4 to 12 per 1000 for older persons) given aspirin for 5 years (10 -12). These controlled trials in primary and secondary prevention settings also suggest that aspirin increases rates of hemorrhagic strokes by a small amount (0 to 2 per 1000 persons given aspirin for 5 years) (5-7). Such estimates are less reliable than those of gastrointestinal bleeding because few strokes were reported in the trials.
RECOMMENDATIONS OF OTHER ORGANIZATIONS
In 1994, the Canadian Task Force on Preventive Health Care concluded that the evidence was not strong enough to recommend for or against use of aspirin for primary prevention of heart disease in men or women and recommended that physicians and patients balance the reduced rate of nonfatal myocardial infarction against potential adverse effects (13). In 2000, the American Diabetes Association recommended that clinicians consider aspirin for primary prevention of heart disease in diabetic patients who are older than 30 years of age or have risk factors for cardiovascular disease and no contraindications to aspirin therapy (14). In 1997, the American Heart Association concluded that aspirin may be warranted for patients at high risk for myocardial infarction but that health care providers must consider a patient's particular cardiovascular risk profile, the demonstrated benefits of aspirin on reducing risk for a first myocardial infarction, and known and unknown side effects of aspirin (15) . In 1998, the European Society of Cardiology recommended low-dose aspirin (75 mg) for patients with well-controlled hypertension and men at "particularly" high risk for coronary heart disease, but not for all persons at high risk (16). 
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